H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, pp.1627-1666, 2015.

J. Brahmer, K. L. Reckamp, and P. Baas, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, pp.123-158, 2015.

R. S. Herbst, P. Baas, and D. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-50, 2016.

M. Reck, D. Rodríguez-abreu, and A. G. Robinson, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016.

L. Gandhi, D. Rodríguez-abreu, and S. Gadgeel, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, pp.2078-92, 2018.

J. D. Patel, M. A. Socinski, and E. B. Garon, PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, pp.4349-57, 2013.

, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, 2018.

S. Champiat, L. Dercle, and S. Ammari, Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, pp.1920-1928, 2017.

L. Mezquita, E. Auclin, and R. Ferrara, Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced NonSmall Cell Lung Cancer, JAMA Oncol, 2018.

H. Rizvi, F. Sanchez-vega, and K. La, Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J Clin Oncol Off J Am Soc Clin Oncol, 2018.

J. Garde-noguera, P. M. Martorell, D. Julián, and M. , Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients, Clin Transl Oncol, 2018.

V. Hoff, D. D. Stephenson, J. J. Rosen, and P. , Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers, J Clin Oncol, vol.28, pp.4877-83, 2010.

A. Rittmeyer, F. Barlesi, and D. Waterkamp, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-65, 2017.

M. Tamiya, A. Tamiya, and T. Inoue, Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial, PLOS ONE, vol.13, p.192227, 2018.

M. Riihimäki, A. Hemminki, and M. Fallah, Metastatic sites and survival in lung cancer, Lung Cancer, vol.86, pp.78-84, 2014.

R. Ferrara, L. Mezquita, and M. Texier, Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy, JAMA Oncol, 2018.

E. B. Garon, T. Ciuleanu, and O. Arrieta, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, doubleblind, randomised phase 3 trial, Lancet Lond Engl, vol.384, pp.665-73, 2014.

M. Reck, R. Kaiser, and A. Mellemgaard, Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, Lancet Oncol, vol.15, pp.143-55, 2014.

E. Giroux-leprieur, A. M. Vieira, and T. , Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinumbased chemotherapy, Lung Cancer Amst Neth, vol.79, pp.167-72, 2013.

R. L. Ferris, G. Blumenschein, and J. Fayette, Nivolumab for Recurrent SquamousCell Carcinoma of the Head and Neck, N Engl J Med, vol.375, pp.1856-67, 2016.

G. Schvartsman, S. A. Peng, and G. Bis, Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer, Données Épidémiologique : -Globocan.iarc.fr, 2017.

S. Novello, F. Barlesi, and R. Califano, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.27, pp.1-27, 2016.

S. J. Antonia, A. Villegas, and D. Daniel, Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.377, pp.1919-1948, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01753457

M. Li, Q. Zhang, and P. Fu, Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials, PloS One, vol.7, p.37229, 2012.

N. Hanna, F. A. Shepherd, and F. V. Fossella, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol Off J Am Soc Clin Oncol, vol.22, pp.1589-97, 2004.

F. A. Shepherd, J. Dancey, and R. Ramlau, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, pp.2095-103, 2000.

E. Quoix, G. Zalcman, and J. Oster, Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced nonsmall-cell lung cancer: IFCT-0501 randomised, Lancet Lond Engl, vol.378, pp.1079-88, 2011.

, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, 2018.

J. D. Patel, M. A. Socinski, and E. B. Garon, PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, pp.4349-57, 2013.

A. Lima, L. T. Macedo, and A. D. Sasse, Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis, PloS One, vol.6, p.22681, 2011.

A. Ilhan-mutlu, M. Osswald, and Y. Liao, Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma, Mol Cancer Ther, vol.15, pp.702-712, 2016.

A. B. Cortot, C. Audigier-valette, and O. Molinier, Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE, J Clin Oncol, vol.34, pp.9005-9005, 2016.

E. B. Garon, T. Ciuleanu, and O. Arrieta, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, doubleblind, randomised phase 3 trial, Lancet Lond Engl, vol.384, pp.665-73, 2014.

M. Reck, R. Kaiser, and A. Mellemgaard, Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, Lancet Oncol, vol.15, pp.143-55, 2014.

A. Morabito, Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients, BMC Med, vol.16, 2018.

J. Soria, Y. Ohe, and J. Vansteenkiste, Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, pp.113-138, 2018.

S. Peters, D. R. Camidge, and A. T. Shaw, Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.377, pp.829-867, 2017.

A. Leonetti, F. Facchinetti, and G. Rossi, BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall, Cancer Treat Rev, vol.66, pp.82-94, 2018.

J. Mazières, F. Barlesi, and T. Filleron, Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort, Ann Oncol Off J Eur Soc Med Oncol, vol.27, pp.281-287, 2016.

R. Ferrara, N. Auger, E. Auclin, and B. Besse, Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.13, pp.27-45, 2018.

, Patients with Metastatic Melanoma | NEJM, vol.25, 2018.

, Nivolumab plus Ipilimumab in Advanced Melanoma | NEJM

, Aug, vol.25, 2018.

O. Hamid, C. Robert, and A. Daud, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, vol.369, pp.134-178, 2013.

C. Robert, J. Schachter, and G. V. Long, Pembrolizumab versus Ipilimumab in Advanced Melanoma, 2015.

T. A. Leal and S. S. Ramalingam, Immunotherapy in previously treated non-small cell lung cancer (NSCLC), J Thorac Dis, vol.10, pp.422-454, 2018.

H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, pp.1627-1666, 2015.

L. Horn, D. R. Spigel, and E. E. Vokes, Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials

, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, pp.3924-3957, 2017.

D. P. Carbone, M. Reck, and L. Paz-ares, First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med, vol.376, pp.2415-2441, 2017.

, Neoadjuvant PD-1 Blockade in Resectable Lung Cancer | NEJM, 2018.

M. Delaunay, J. Cadranel, and A. Lusque, Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients, Eur Respir J, vol.50, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01819272

R. S. Herbst, P. Baas, and D. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-50, 2016.

M. Reck, D. Rodríguez-abreu, and A. G. Robinson, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016.

L. Gandhi, D. Rodríguez-abreu, and S. Gadgeel, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, pp.2078-92, 2018.

J. R. Brahmer, R. Govindan, and R. A. Anders, The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC), J Immunother Cancer, vol.6, 2018.

L. Fehrenbacher, A. Spira, and M. Ballinger, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet Lond Engl, vol.387, pp.1837-1883, 2016.

A. Rittmeyer, F. Barlesi, and D. Waterkamp, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-65, 2017.

M. A. Socinski, R. M. Jotte, and F. Cappuzzo, Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.378, pp.2288-301, 2018.

J. Brahmer, K. L. Reckamp, and P. Baas, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, pp.123-158, 2015.

E. Giroux-leprieur, A. M. Vieira, and T. , Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinumbased chemotherapy, Lung Cancer Amst Neth, vol.79, pp.167-72, 2013.

H. Zhou, Y. Dai, and L. Zhu, Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC, J Int Med Res, vol.44, pp.89-98, 2016.

C. Pérez-ramírez, M. Cañadas-garre, and A. Alnatsha, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients, Curr Opin Pharmacol, vol.6, pp.350-354, 2006.

X. Armoiry, A. Tsertsvadze, and M. Connock, Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis, PloS One, vol.13, p.199575, 2018.

P. N. Aguiar, D. Mello, R. A. Hall, P. Tadokoro, H. et al., PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data, Immunotherapy, vol.9, pp.499-506, 2017.

F. R. Hirsch, A. Mcelhinny, and D. Stanforth, PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.12, pp.208-230, 2017.

J. Adam, L. Stang, N. Rouquette, and I. , Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer, Ann Oncol Off J Eur Soc Med Oncol, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01926681

N. A. Rizvi, M. D. Hellmann, and A. Snyder, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-132, 2015.

S. Champiat, C. Ferté, S. Lebel-binay, A. Eggermont, and J. C. Soria, Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy, Oncoimmunology, vol.3, p.27817, 2014.

R. J. Motzer, N. M. Tannir, and D. F. Mcdermott, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.378, pp.1277-90, 2018.

M. D. Hellmann, T. Ciuleanu, and A. Pluzanski, Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med, vol.378, pp.2093-104, 2018.

L. Mezquita, E. Auclin, and R. Ferrara, Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer, JAMA Oncol, 2018.

A. Russo, T. Franchina, and G. Ricciardi, Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel, Hallmarks of Cancer: The Next Generation: Cell

T. Kobayashi, M. Teruya, and T. Kishiki, Inflammation-based prognostic score and number of lymph node metastases are independent prognostic factors in esophageal squamous cell carcinoma, Dig Surg, vol.27, pp.232-239, 2010.

M. Tomita, T. Shimizu, T. Ayabe, A. Yonei, and T. Onitsuka, Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer, Anticancer Res, vol.31, pp.2995-3003, 2011.

B. A. Ozyurek, T. S. Ozdemirel, S. B. Ozden, Y. Erdogan, B. Kaplan et al.,

, Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases, Asian Pac J Cancer Prev APJCP, vol.18, pp.1417-1438, 2017.

J. Kargl, S. E. Busch, and G. Yang, Neutrophils dominate the immune cell composition in non-small cell lung cancer, Nat Commun, vol.8, 2017.

K. H. Kang, J. T. Efird, and N. Sharma, Prognostic potential of neutrophil-tolymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer, Future Oncol, vol.13, pp.1405-1419, 2017.

M. Riihimäki, A. Hemminki, and M. Fallah, Metastatic sites and survival in lung cancer, Lung Cancer, vol.86, pp.78-84, 2014.

M. Tamiya, A. Tamiya, and T. Inoue, Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial, PLOS ONE, vol.13, p.192227, 2018.

S. Gettinger, L. Horn, and D. Jackman, Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study, J Clin Oncol Off J Am Soc Clin Oncol, p.2017770412, 2018.

J. Garde-noguera, P. M. Martorell, D. Julián, and M. , Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients, Clin Transl Oncol, 2018.

K. Nakahama, S. Isa, and A. Tamiya, The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter, Anticancer Res, vol.37, pp.5885-91, 2017.

T. Inoue, M. Tamiya, and A. Tamiya, Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab, Clin Lung Cancer, vol.19, pp.171-177, 2018.

C. Kaderbhai, C. Richard, and J. D. Fumet, Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer, Oncoimmunology, vol.6, p.1339856, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01694057

D. Cortinovis, V. Gregorc, and M. R. Migliorino, New perspectives in the secondline treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group, Crit Rev Oncol Hematol, vol.109, pp.35-41, 2017.

L. Seymour, J. Bogaerts, and A. Perrone, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, pp.143-52, 2017.

S. Champiat, L. Dercle, and S. Ammari, Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, pp.1920-1928, 2017.

R. Ferrara, L. Mezquita, and M. Texier, Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy, JAMA Oncol, 2018.

K. Haratani, H. Hayashi, and Y. Chiba, Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol, 2018.

G. Schvartsman, S. A. Peng, and G. Bis, Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer, Lung Cancer, 2017.

A. Calles, X. Liao, and L. M. Sholl, Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.10, pp.1726-1761, 2015.

L. Julien-mazieres-alexander-e-drilon and . Mhanna, Immune checkpoint inhibitors for patients with advanced lung adenocarcinoma and oncogenic driver alterations: results from the global IMMUNOTARGET registry

R. L. Ferris, G. Blumenschein, and J. Fayette, Nivolumab for Recurrent SquamousCell Carcinoma of the Head and Neck, N Engl J Med, vol.375, pp.1856-67, 2016.

E. Saâda-bouzid, C. Defaucheux, and A. Karabajakian, Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, 75 Perspectives from ASCO 2018: Immunotherapy research in oncogene driven NSCLC, The ImmunoTarget and early combination study | OncologyPRO, vol.28, pp.1605-1616, 2017.

A. Badawy, A. Khedr, G. Omar, A. Bae, S. Arafat et al., Site of Metastases as Prognostic Factors in Unselected Population of Stage IV Non-Small Cell Lung Cancer, Asian Pac J Cancer Prev APJCP, vol.19, pp.1907-1917, 2018.

P. C. Tumeh, M. D. Hellmann, and O. Hamid, Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC, Cancer Immunol Res, vol.5, pp.417-441, 2017.